Revvity Research and Development Expenses 2012-2026 | RVTY
Revvity annual/quarterly research and development expenses history and growth rate from 2012 to 2026. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Revvity research and development expenses for the quarter ending March 31, 2026 were $0.058B, a 8% increase year-over-year.
- Revvity research and development expenses for the twelve months ending March 31, 2026 were $0.220B, a 10.02% increase year-over-year.
- Revvity annual research and development expenses for 2025 were $0.216B, a 9.65% increase from 2024.
- Revvity annual research and development expenses for 2024 were $0.197B, a 9.11% decline from 2023.
- Revvity annual research and development expenses for 2023 were $0.217B, a 2.27% decline from 2022.
|
Revvity Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2025 | $216 |
| 2024 | $197 |
| 2023 | $217 |
| 2022 | $222 |
| 2021 | $200 |
| 2020 | $146 |
| 2019 | $189 |
| 2018 | $194 |
| 2017 | $139 |
| 2016 | $124 |
| 2015 | $113 |
| 2014 | $108 |
| 2013 | $132 |
| 2012 | $132 |
| 2011 | $116 |
|
Revvity Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2026-03-31 | $58 |
| 2025-12-31 | $58 |
| 2025-09-30 | $51 |
| 2025-06-30 | $53 |
| 2025-03-31 | $54 |
| 2024-12-31 | $49 |
| 2024-09-30 | $49 |
| 2024-06-30 | $48 |
| 2024-03-31 | $50 |
| 2023-12-31 | $50 |
| 2023-09-30 | $53 |
| 2023-06-30 | $57 |
| 2023-03-31 | $57 |
| 2022-12-31 | $55 |
| 2022-09-30 | $54 |
| 2022-06-30 | $56 |
| 2022-03-31 | $58 |
| 2021-12-31 | $25 |
| 2021-09-30 | $49 |
| 2021-06-30 | $66 |
| 2021-03-31 | $60 |
| 2020-12-31 | $-2 |
| 2020-09-30 | $50 |
| 2020-06-30 | $50 |
| 2020-03-31 | $49 |
| 2019-12-31 | $48 |
| 2019-09-30 | $45 |
| 2019-06-30 | $48 |
| 2019-03-31 | $48 |
| 2018-12-31 | $52 |
| 2018-09-30 | $49 |
| 2018-06-30 | $47 |
| 2018-03-31 | $46 |
| 2017-12-31 | $38 |
| 2017-09-30 | $35 |
| 2017-06-30 | $34 |
| 2017-03-31 | $33 |
| 2016-12-31 | $33 |
| 2016-09-30 | $30 |
| 2016-06-30 | $32 |
| 2016-03-31 | $30 |
| 2015-12-31 | $17 |
| 2015-09-30 | $31 |
| 2015-06-30 | $33 |
| 2015-03-31 | $32 |
| 2014-12-31 | $18 |
| 2014-09-30 | $30 |
| 2014-06-30 | $30 |
| 2014-03-31 | $29 |
| 2013-12-31 | $32 |
| 2013-09-30 | $31 |
| 2013-06-30 | $34 |
| 2013-03-31 | $34 |
| 2012-12-31 | $33 |
| 2012-09-30 | $32 |
| 2012-06-30 | $34 |
| 2012-03-31 | $33 |
| 2011-12-31 | $32 |
| 2011-09-30 | $30 |
| 2011-06-30 | $28 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.039B | $2.856B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.187B | 24.31 |
| HCA Healthcare (HCA) | United States | $110.772B | 17.53 |
| CVS Health (CVS) | United States | $101.670B | 11.75 |
| Elevance Health (ELV) | United States | $68.432B | 10.33 |
| Cencora (COR) | United States | $62.409B | 19.63 |
| Natera (NTRA) | United States | $27.358B | 0.00 |
| Labcorp Holdings (LH) | United States | $21.501B | 15.87 |
| DiDi Global (DIDIY) | China | $18.026B | 15.96 |
| Viatris (VTRS) | United States | $15.685B | 5.71 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.535B | 0.00 |
| Medpace Holdings (MEDP) | United States | $14.094B | 32.26 |
| BioMerieux (BMXMF) | France | $12.476B | 0.00 |
| Solventum (SOLV) | United States | $11.408B | 10.78 |
| BrightSpring Health Services (BTSG) | United States | $8.774B | 43.59 |
| Charles River Laboratories (CRL) | United States | $8.667B | 17.09 |
| ICON (ICLR) | Ireland | $8.626B | 8.56 |
| CochLear (CHEOY) | Australia | $8.030B | 0.00 |
| Sonic Healthcare (SKHHY) | Australia | $6.905B | 0.00 |
| HealthEquity (HQY) | United States | $6.586B | 23.20 |
| Bausch + Lomb (BLCO) | Canada | $5.877B | 32.98 |
| GETINGE (GNGBY) | Sweden | $5.626B | 17.96 |
| Avantor (AVTR) | United States | $5.388B | 8.68 |
| PACS (PACS) | United States | $5.304B | 27.44 |
| Caris Life Sciences,�Inc (CAI) | United States | $5.101B | 0.00 |
| Sotera Health (SHC) | United States | $4.380B | 19.95 |
| Alignment Healthcare (ALHC) | United States | $4.188B | 0.00 |
| Concentras Parent (CON) | United States | $2.818B | 16.12 |
| Organon (OGN) | United States | $2.299B | 2.57 |
| Amplifon S.p.A (AMFPF) | Italy | $2.275B | 13.27 |
| Pediatrix Medical (MD) | United States | $1.782B | 11.11 |
| Establishment Labs Holdings (ESTA) | United States | $1.765B | 0.00 |
| GeneDx Holdings (WGS) | United States | $1.746B | 42.28 |
| Surgery Partners (SGRY) | United States | $1.671B | 41.65 |
| Sonida Senior Living (SNDA) | United States | $1.544B | 0.00 |
| Ardent Health (ARDT) | United States | $1.345B | 5.70 |
| Progyny (PGNY) | United States | $1.277B | 25.08 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.240B | 0.00 |
| InnovAge Holding (INNV) | United States | $1.113B | 164.00 |
| Teladoc Health (TDOC) | United States | $0.920B | 0.00 |
| CareDx (CDNA) | United States | $0.822B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $0.750B | 12.17 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Nutex Health (NUTX) | United States | $0.704B | 11.25 |
| Omada Health (OMDA) | United States | $0.672B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.604B | 99.85 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.531B | 0.00 |
| Embecta (EMBC) | United States | $0.524B | 2.92 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.497B | 0.00 |
| CryoPort (CYRX) | United States | $0.482B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.435B | 4.70 |
| SBC Medicals (SBC) | United States | $0.426B | 8.47 |
| Forward Industries (FWDI) | United States | $0.375B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.349B | 0.00 |
| Agilon Health (AGL) | United States | $0.316B | 0.00 |
| Shoulder Innovations (SI) | United States | $0.309B | 0.00 |
| Oncology Institute (TOI) | United States | $0.304B | 0.00 |
| So-Young (SY) | China | $0.262B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Biodesix (BDSX) | United States | $0.133B | 0.00 |
| Beauty Health (SKIN) | United States | $0.115B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.091B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.080B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.077B | 0.00 |
| DocGo (DCGO) | United States | $0.051B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.037B | 0.00 |
| Pomdoctor - (POM) | China | $0.031B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.026B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.018B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.015B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Lifeward (LFWD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.009B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.007B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Co-Diagnostics (CODX) | United States | $0.005B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |